首页> 外文OA文献 >Afatinib plus bevacizumab combination after acquired resistance to EGFR tyrosine kinase inhibitors in EGFR -mutant non-small cell lung cancer: Multicenter, single-arm, phase 2 trial (ABC Study)

【2h】

Afatinib plus bevacizumab combination after acquired resistance to EGFR tyrosine kinase inhibitors in EGFR -mutant non-small cell lung cancer: Multicenter, single-arm, phase 2 trial (ABC Study)

机译：AFATINIB加上贝伐单抗组合后获得抗EGFR酪氨酸激酶抑制剂在EGFR-富富小细胞肺癌中的抗性：多中心，单臂，2阶段试验（ABC研究）

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Akito Hata; Nobuyuki Katakami; Reiko Kaji; Toshihide Yokoyama; Toshihiko Kaneda; Motohiro Tamiya; Takako Inoue; Hiromi Kimura; Yukihiro Yano; Daisuke Tamura; Satoshi Morita; Shunichi Negoro; for the HANSHIN Oncology Group;
展开▼
作者单位

展开▼
年度 2018
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
专利

1. Afatinib plus bevacizumab combination after acquired resistance to EGFR tyrosine kinase inhibitors in EGFR EGFR ‐mutant non–small cell lung cancer: Multicenter, single‐arm, phase 2 trial (ABC Study) [J] . Hata Akito, Katakami Nobuyuki, Kaji Reiko, Cancer: A Journal of the American Cancer Society . 2018,第19期

机译：AFATINIB加上EGFR酪氨酸激酶抑制剂在EGFR EGFR-矫制性非小细胞癌中的抗性后的抗叶蜡蛋白组合：多中心，单臂，第2阶段试验（ABC研究）
2. Activity of the EGFR-HER2 Dual Inhibitor Afatinib in EGFR-Mutant Lung Cancer Patients With Acquired Resistance to Reversible EGFR Tyrosine Kinase Inhibitors [J] . Landi Lorenza, Tiseo Marcello, Chiari Rita, Clinical lung cancer . 2014,第6期

机译：EGFR-突变型肺癌对可逆EGFR酪氨酸激酶抑制剂具有耐药性的EGFR突变型肺癌患者中EGFR-HER2双重抑制剂Afatinib的活性
3. Radiofrequency Ablation with Continued EGFR Tyrosine Kinase Inhibitor Therapy Prolongs Disease Control in EGFR-Mutant Advanced Lung Cancers with Acquired Resistance to EGFR Tyrosine Kinase Inhibitors: Two Case Reports [J] . Xuefei Shi, Jia Zhou, Caihua Qian, OncoTargets and therapy . 2020,第2期

机译：持续EGFR酪氨酸激酶抑制剂治疗的射频消融促进EGFR-突变生物晚期肺癌的疾病对照，获得EGFR酪氨酸激酶抑制剂的抗性：两种情况报告
4. Association between tumor heterogeneity and progression-free survival in non-small cell lung cancer patients with EGFR mutations undergoing tyrosine kinase inhibitors therapy [C] . Jiangdian Song, Di Dong, Yanqi Huang, Annual International Conference of the IEEE Engineering in Medicine and Biology Society . 2016

机译：接受酪氨酸激酶抑制剂治疗的EGFR突变非小细胞肺癌患者肿瘤异质性与无进展生存的关系
5. EGFR in Early Non-Small Cell Lung Cancer: Tyrosine Kinase Inhibition in a Neoadjuvant Trial. [D] . Lara-Guerra, Humberto. 2011

机译：早期非小细胞肺癌中的EGFR：新辅助试验中酪氨酸激酶抑制作用。
6. Intrinsic Resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance [O] . Eric Santoni-Rugiu, Linea C. Melchior, Edyta M. Urbanska, 2019

机译：EGFR突变型非小细胞肺癌中对EGFR酪氨酸激酶抑制剂的内在抗性：获得性抗性的异同
7. Afatinib (Afa) plus bevacizumab (Bev) combination after acquired resistance (AR) to EGFR-tyrosine kinase inhibitors (TKIs) in EGFR-mutant non-small cell lung cancer (NSCLC): Multicenter single arm phase II trial (ABC-study) [O] . M. Tamiya, A. Hata, N. Katakami, 2017

机译：AFATINIB（AFA）加上贝伐单抗（BEV）组合在收购抗原（AR）到EGFR-突变体非小细胞肺癌（NSCLC）中的EGFR-酪氨酸激酶抑制剂（TKIS）：多中心单臂第二次审判（ABC-SCOULE）

Afatinib plus bevacizumab combination after acquired resistance to EGFR tyrosine kinase inhibitors in EGFR -mutant non-small cell lung cancer: Multicenter, single-arm, phase 2 trial (ABC Study)

著录项

引文网络

相似文献

相关主题

期刊订阅